Role of Vitamin K2 in the Development of Hepatocellular Carcinoma in Women With Viral Cirrhosis of the Liver
- 21 July 2004
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (3) , 358-361
- https://doi.org/10.1001/jama.292.3.358
Abstract
Research from JAMA — Role of Vitamin K2 in the Development of Hepatocellular Carcinoma in Women With Viral Cirrhosis of the Liver — ContextPrevious findings indicate that vitamin K2 (menaquinone) may play a role in controlling cell growth.ObjectiveTo determine whether vitamin K2has preventive effects on the development of hepatocellular carcinoma in women with viral cirrhosis of the liver.Design, Setting, and ParticipantsForty women diagnosed as having viral liver cirrhosis were admitted to a university hospital between 1996 and 1998 and were randomly assigned to the treatment or control group. The original goal of the trial was to assess the long-term effects of vitamin K2 on bone loss in women with viral liver cirrhosis. However, study participants also satisfied criteria required for examination of the effects of such treatment on the development of hepatocellular carcinoma.InterventionsThe treatment group received 45 mg/d of vitamin K2 (n = 21). Participants in the treatment and control groups received symptomatic therapy to treat ascites, if necessary, and dietary advice.Main Outcome MeasureCumulative proportion of patients with hepatocellular carcinoma.ResultsHepatocellular carcinoma was detected in 2 of the 21 women given vitamin K2 and 9 of the 19 women in the control group. The cumulative proportion of patients with hepatocellular carcinoma was smaller in the treatment group (log-rank test, P = .02). On univariate analysis, the risk ratio for the development of hepatocellular carcinoma in the treatment group compared with the control group was 0.20 (95% confidence interval [CI], 0.04-0.91; P = .04). On multivariate analysis with adjustment for age, alanine aminotransferase activity, serum albumin, total bilirubin, platelet count, α-fetoprotein, and history of treatment with interferon alfa, the risk ratio for the development of hepatocellular carcinoma in patients given vitamin K2 was 0.13 (95% CI, 0.02-0.99; P = .05).ConclusionThere is a possible role for vitamin K2 in the prevention of hepatocellular carcinoma in women with viral cirrhosis.Keywords
This publication has 9 references indexed in Scilit:
- Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitaminJournal of Cellular Physiology, 2000
- Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosisJournal of Hepatology, 2000
- Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in JapanAnnals of Internal Medicine, 1999
- Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: A double-blind placebo-controlled studyJournal of Bone and Mineral Metabolism, 1998
- Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosisPublished by Elsevier ,1995
- Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6Nature, 1995
- Geranylgeraniol Is a Potent Inducer of Apoptosis in Tumor CellsThe Journal of Biochemistry, 1995
- Novel Role of Vitamin K2: A Potent Inducer of Differentiation of Various Human Myeloid Leukemia Cell LinesBiochemical and Biophysical Research Communications, 1994
- Compensated cirrhosis: Natural history and prognostic factorsHepatology, 1987